Press release by OBI Pharma
OBI Pharma, Inc. (TPEx: 4174) announced scientific data highlighting the antitumor synergy of OBI-3424 in combination with pembrolizumab (PD-1) and the association of high Globo H and PD-L1 expression resulting in poor survival in gastric cancer patients, will be presented at the American Association of Cancer Research (AACR) Annual Meeting from April 8–13, 2022 in New Orleans, LA. (USA).
OBI’s Chief Scientific Officer, Ming-Tain Lai, Ph. D stated that “OBI Pharma is proud to present at the AACR Annual Meeting our latest scientific findings on the efficacy of OBI-3424 and the role of the Globo H antigen. OBI-3424 can induce immunogenic cell death and demonstrated impressive synergistic efficacy in combination with Pembrolizumab in various cancer models. Emerging science also demonstrated poor survival in gastric cancer patients who have high Globo H and PD-L1 expression. These findings warrant potential combination therapeutic strategies of OBI-3424 as well as anti-Globo H plus PD-1/PD-L1 cancer therapeutics ”.
More information on OBI's presentation: https://www.obipharma.com/news